Amylyx Pharmaceuticals, Inc. AMLX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amylyx Pharmaceuticals, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amylyx Pharmaceuticals, Inc.'s cash & equivalents?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported cash & equivalents of $229.14M in Q1 2026.
- How has Amylyx Pharmaceuticals, Inc.'s cash & equivalents changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s cash & equivalents increased by 283.4% year-over-year, from $59.76M to $229.14M.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s cash & equivalents?
- Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s cash & equivalents has grown at a 45.8% compound annual growth rate (CAGR), from $50.19M to $226.65M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.